Skip to content

Comparative in vivo evaluation of 2 formulations of Silymarin 210 mg

Comparative bioequivalence study of Silymarin 210 mg Softgel of Gol Darou Pharmaceutical Co. and Silymarin 210 Hard Capsule of Gol Darou Pharmaceutical Co. in 24 healthy male under fasting

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180620040164N88
Enrollment
24
Registered
2025-05-14
Start date
2025-06-09
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poisoning by other drugs, medicaments and biological substances, accidental (unintentional). Poisoning by other drugs, medicaments and biological substances, accidental (unintentional)

Interventions

Intervention 1: Intervention group: Silymarin 210 mg softgel , produced by Gol Darou Pharmaceutical Co. In each period, 12 of 24 subjects will be given single oral dose of this product. After 14-day w

Sponsors

Gol Darou Pharmaceutical Co.
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Healthy subjects (male) between 18– 55 years of age. Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m2. Subjects with normal vital signs. Subjects who agree with patient consent form.

Exclusion criteria

Exclusion criteria: Subjects with known allergy to the products tested. Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period. Subjects who has used any prescription or OTC drugs 14 days prior to the initiation of study and unable to refrain from the concomitant medications. History of alcohol or drug abuse. Heavy drinker of caffeine, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity. A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study

Design outcomes

Primary

MeasureTime frame
Peak Plasma Concentration (Cmax). Timepoint: 18 blood samples will be withdrawn pre-dose and at 0, 0.25, 0.5, 0.75, 1, 1.33, 1.66, 2, 4, 6, 8, 11, 24. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).

Secondary

MeasureTime frame
AUC (Area Under the Concentration-Time Curve). Timepoint: 13 blood samples will be withdrawn pre-dose and at 0, 0.25, 0.5, 0.75, 1, 1.33, 1.66, 2, 4, 6, 8, 11, 24. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Montaha Sangari

Noor research and educational institute (Tavan)

info@tavaninstitute.ir+98 21 6600 7026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026